Federated Hermes Inc. Reduces Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Federated Hermes Inc. cut its stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 99.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,067 shares of the specialty pharmaceutical company's stock after selling 327,426 shares during the quarter. Federated Hermes Inc.'s holdings in Collegium Pharmaceutical were worth $88,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of COLL. Barclays PLC boosted its holdings in shares of Collegium Pharmaceutical by 152.2% in the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company's stock valued at $2,899,000 after buying an additional 45,291 shares during the last quarter. Geode Capital Management LLC lifted its position in Collegium Pharmaceutical by 0.7% during the third quarter. Geode Capital Management LLC now owns 775,579 shares of the specialty pharmaceutical company's stock worth $29,974,000 after purchasing an additional 5,464 shares during the period. Sanctuary Advisors LLC increased its position in Collegium Pharmaceutical by 10.7% during the 3rd quarter. Sanctuary Advisors LLC now owns 17,976 shares of the specialty pharmaceutical company's stock worth $695,000 after purchasing an additional 1,731 shares in the last quarter. Franklin Resources Inc. increased its position in Collegium Pharmaceutical by 13.4% in the 3rd quarter. Franklin Resources Inc. now owns 30,625 shares of the specialty pharmaceutical company's stock valued at $1,164,000 after acquiring an additional 3,620 shares during the period. Finally, Principal Financial Group Inc. boosted its stake in shares of Collegium Pharmaceutical by 3.9% in the 3rd quarter. Principal Financial Group Inc. now owns 1,745,818 shares of the specialty pharmaceutical company's stock valued at $67,459,000 after purchasing an additional 64,958 shares during the last quarter.

Collegium Pharmaceutical Price Performance

Shares of Collegium Pharmaceutical stock traded up $0.49 during trading on Thursday, hitting $26.48. The stock had a trading volume of 34,647 shares, compared to its average volume of 414,768. The firm has a market cap of $850.82 million, a price-to-earnings ratio of 11.41 and a beta of 0.76. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a 12 month low of $23.23 and a 12 month high of $42.29. The business's 50-day moving average is $28.51 and its 200 day moving average is $30.96.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last released its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating analysts' consensus estimates of $1.54 by $0.09. The business had revenue of $181.95 million for the quarter, compared to analysts' expectations of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. As a group, sell-side analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current year.

Insider Buying and Selling

In related news, EVP Shirley R. Kuhlmann sold 26,067 shares of the stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $28.50, for a total transaction of $742,909.50. Following the sale, the executive vice president now directly owns 108,137 shares of the company's stock, valued at $3,081,904.50. This trade represents a 19.42 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CFO Colleen Tupper sold 1,949 shares of the stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $30.00, for a total value of $58,470.00. Following the sale, the chief financial officer now directly owns 177,195 shares in the company, valued at $5,315,850. This trade represents a 1.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 81,693 shares of company stock valued at $2,334,994 over the last ninety days. Company insiders own 2.51% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on COLL shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. Piper Sandler reduced their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a "neutral" rating on the stock in a research note on Tuesday, February 4th. HC Wainwright reissued a "buy" rating and set a $50.00 target price on shares of Collegium Pharmaceutical in a research note on Monday, March 24th. Finally, StockNews.com cut shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a report on Saturday, April 19th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $43.60.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.